BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 2566125)

  • 1. [Is strong inhibition of gastric acid in the treatment of peptic ulcer sensible?].
    de Bruijne JW; Lamers CB
    Ned Tijdschr Geneeskd; 1989 Apr; 133(13):657-62. PubMed ID: 2566125
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical effects and problems; histamine H2 receptor blockaders].
    Tani N; Miwa T
    Nihon Rinsho; 1988 Jan; 46(1):12-7. PubMed ID: 2897482
    [No Abstract]   [Full Text] [Related]  

  • 4. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ulcer disease.
    Spenney JG
    Ala J Med Sci; 1985 Jan; 22(1):49-53. PubMed ID: 3883827
    [No Abstract]   [Full Text] [Related]  

  • 6. [Histamine H2-receptor antagonists as new anti-ulcer agents].
    Takemoto T
    Nihon Rinsho; 1984 Jan; 42(1):103-13. PubMed ID: 6143835
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Histamine H2 receptor blockaders: possibilities and prognosis in the use of stage III-IV preparations in the therapy of internal diseases].
    Miagkova LP; Grebenev AL; Kkhorshed AM
    Klin Med (Mosk); 1991 Mar; 69(3):27-34. PubMed ID: 1676773
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
    De Natale G; De Natale F; Marino A
    Clin Ter; 1989 Apr; 129(1):3-16. PubMed ID: 2567647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer].
    Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA
    Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.
    Thomas JM; Misiewicz G
    Clin Gastroenterol; 1984 May; 13(2):501-41. PubMed ID: 6146417
    [No Abstract]   [Full Text] [Related]  

  • 12. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple approach to assess potentiated drug combinations in clinical trials: studies with pirenzepine plus H2-receptor antagonists.
    Pöch G; Londong W
    Int J Clin Pharmacol Ther Toxicol; 1985 Jun; 23(6):283-7. PubMed ID: 2862111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
    Peterson WL; Harford WV
    Am J Gastroenterol; 1991 Jun; 86(6):671-5. PubMed ID: 1674838
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug therapy of peptic ulcer. What is coming up?].
    Müller P; Dammann HG; Simon B; Kommerell B
    Leber Magen Darm; 1987 Feb; 17(1):50-4. PubMed ID: 3104707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative evaluation of cimetidine and ranitidine.
    Zimmerman TW; Schenker S
    Ration Drug Ther; 1985 Apr; 19(4):1-7. PubMed ID: 2932770
    [No Abstract]   [Full Text] [Related]  

  • 17. Acid reduction in peptic ulcer disease. Choosing therapy according to drug interactions, individual response, and cost.
    Parent K
    Postgrad Med; 1994 Nov; 96(6):53-9. PubMed ID: 7971612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranitidine: a pilot study in Japan.
    Takemoto T; Okazaki Y; Okita K; Namiki M; Ishikawa M; Oshiba S; Kurokawa K
    Scand J Gastroenterol Suppl; 1981 Jun; 69():125-8. PubMed ID: 6119776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
    Corinaldesi R; Ghidini C; Ricci Maccarini M; Santaguida P; Fratesi E; Barbara G; Stanghellini V
    Ital J Gastroenterol; 1990; 22 Suppl 1():2-4. PubMed ID: 1983421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled trial with ranitidine in the treatment of peptic ulcer.
    Nelis GF
    Neth J Med; 1981; 24(6):224-8. PubMed ID: 6119631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.